Arrangements for strategic, technical, manufacturing, or marketing tie up

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com September 18, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/ Madam, Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) This is to inform you that Dr. Reddy's Laboratories Limited ("Dr. Reddy's") has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited ("Takeda") for Qdenga® in the private market in India (the “Agreement”). Qdenga® is a dengue vaccine developed by Takeda to protect against all four dengue virus serotypes. Further, the details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are as hereunder: 1 Name of the entity(ies) with whom Takeda Biopharmaceuticals India Private Limited agreement/ JV is signed 2 Area of agreement/ JV Exclusive distribution and marketing of Qdenga® in the private market in India 3 Domestic/ international Domestic (India) 4 Share exchange ratio/ JV ratio Not applicable 5 Scope of business operation of Pursuant to terms of the Agreement, Dr. Reddy’s will agreement/ JV be exclusively responsible for distribution and marketing of Qdenga® in the private market in India, while Takeda will retain commercialization rights in the public market in India, and will be responsible for manufacturing and importation of the vaccine. 6 Details of consideration paid/ received There is no upfront consideration or milestone in agreement/ JV payment under the agreement. Other commercial terms are confidential in nature. 7 Significant terms and conditions of Pursuant to the terms of the Agreement, Dr. Reddy’s agreement/ JV in brief has exclusive distribution and marketing rights for Qdenga® in the private market in India. 8 Whether the acquisition would fall The transaction at scope is not an acquisition by either within related party transactions and Dr. Reddy’s or Takeda. whether the promoter/ promoter group/ Takeda is not a related party to Dr. Reddy’s or any of group companies have any interest in the its promoter/promoter group/ group companies. entity being acquired? If yes, nature of Further, promoter/promoter group/ group companies interest and details thereof and whether do not have any interest in Takeda. the same is done at “arm’s length 9 Size of the entity(ies) Not applicable 10 Rationale and benefit expected The partnership is aligned with Dr. Reddy's strategy to strengthen its vaccines business in India and supports broader public health efforts aimed at addressing the significant burden of dengue in India. A press release being issued in relation to the above matter is enclosed for reference. This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Encl: As above Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, CONTACT Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 AISHWARYA SITHARAM SANTOSH VYAS Email: mail@drreddys.com AISHWARYASITHARAM@DRREDDYS.COM SANTOSHVYAS@DRREDDYS.COM Web: www.drreddys.com Takeda and Dr. Reddy’s Laboratories Enter into Exclusive Collaboration to Promote and Distribute QDENGA® in India’s Pediatric and Adult Private Market • QDENGA is India’s first CDSCO approved dengue vaccine • Collaboration focuses on disease awareness, promotion and distribution of Takeda’s dengue vaccine, across India’s private market for pediatric and adult vaccination, ahead of its anticipated availability in the first half of 2027 • Collaboration combines Takeda’s global dengue and vaccine expertise with Dr. Reddy’s extensive healthcare network and commercial reach across India Hyderabad, India; September 18, 2026: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) and Takeda Pharmaceutical Company Limited, through its Indian subsidiary Takeda Biopharmaceuticals India Private Limited (together referred to as “Takeda”) today entered into a distribution agreement under which Dr. Reddy’s will promote and distribute Takeda’s dengue vaccine, QDENGA®, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027. The collaboration follows the approval of QDENGA’s marketing authorization by India’s Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India’s first approved dengue vaccine, the approval marks an important milestone in the country’s efforts to strengthen dengue prevention and management. Takeda is committed to supporting the country’s long-term dengue control efforts and enabling broad, equitable access to QDENGA. While inclusion in India’s public immunization program remains an important long-term ambition, private- market availability through Dr. Reddy’s will provide a pathway for eligible individuals to access the vaccine once it becomes available. Through the collaboration, Takeda and Dr. Reddy’s will support healthcare-professional engagement, disease awareness, promotion and distribution of QDENGA across India’s private market for pediatric and adult vaccination, in accordance with applicable regulatory requirements. Addressing India’s growing dengue burden Dengue remains a significant and evolving public-health challenge in India, with reported cases increasing 11-fold over the past two decades.1 According to a nationwide dengue surveillance study conducted by the Virus Research and Diagnostic Laboratory of the Indian Council of Medical Research, all four dengue virus serotypes (DENV-1 to DENV-4) are co-circulating across multiple regions in India, with 1 in 14, patients being infected with multiple dengue serotypes concurrently.2 With dengue cases occurring year-round across India, dengue prevention and management is an urgent public-health priority. M.V. Ramana, CEO - Global Generics, Dr. Reddy’s Laboratories said, “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape. Through our collaboration with Takeda, we look forward to making QDENGA available to eligible individuals and contributing to efforts aimed at addressing the country’s dengue burden.” Dr. Mahender Nayak, Head of Intercontinental Markets, International Business Unit Takeda said, “Takeda is committed to supporting India’s evolving healthcare needs and expanding access to dengue vaccination. We welcome the recent Parliamentary Committee on Health’s recommendation to consider dengue vaccine for the Universal Immunization Program.3 This reflects the growing recognition of dengue as a significant public health challenge. In parallel, our private-market collaboration with Dr. Reddy’s will help enable timely private-market access for eligible individuals once QDENGA becomes available in India.” Complementary strengths to amplify impact In preparation for the anticipated availability of the vaccine in India in the first half of 2027, the strategic collaboration brings together Takeda’s and Dr. Reddy’s complementary strengths, established capabilities, and shared commitment to improving patient access in India. Takeda, [Showing first 8,000 characters — download PDF for full document]